May 13, 2026
After more than a decade of global research and consultation, polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome, or PMOS. The change, published in The Lancet, reflects a deeper understanding of what this condition actually is and why the old name was doing women a disservice.
Why the Old Name Was the Problem
The term "polycystic ovary syndrome" has been in use for decades. But researchers and clinicians have long recognised that it paints the wrong picture. It implies the condition is primarily about cysts on the ovaries. However, a companion paper published alongside the renaming study confirmed that there is no actual increase in abnormal ovarian cysts in people with the condition.
The old name contributed to delayed diagnosis, fragmented care and unnecessary stigma. Many women spent years being told their symptoms were related to weight or stress, when in fact they were living with a complex hormonal disorder that affects multiple body systems at once.
What PMOS Actually Involves
The new name, Polyendocrine Metabolic Ovarian Syndrome or PMOS is designed to reflect how wide-reaching the condition truly is. PMOS affects one in eight women worldwide, totalling more than 170 million people and its effects extend well beyond the reproductive system.
People with PMOS may experience:
- hormonal imbalances involving androgens, insulin and other endocrine signals
- metabolic challenges including insulin resistance and weight changes
- irregular or absent periods and fertility difficulties
- skin concerns such as acne and excess hair growth
- mental health impacts including anxiety and depression
-
sleep disruption and chronic fatigue
This breadth of symptoms explains why so many women bounce between specialists, seeing a gynaecologist for one symptom, a dermatologist for another and an endocrinologist for a third, without ever receiving a unified picture of their health.
How the Name Was Changed
This was not a decision made quickly or lightly. The process, led by Professor Helena Teede from Monash University alongside 56 patient and professional organisations worldwide, took 14 years. It involved iterative global surveys gathering over 22,000 responses from patients and health professionals across all world regions, modified Delphi consensus methods, and workshops that tested different naming options for accuracy, cultural appropriateness and clarity.
Agreement on the new name was reached in February 2026 and a formal transition roadmap has been developed to support adoption across clinical practice, education, research and public communication over the next three years.
What This Means for Everyday Health
For anyone who has been diagnosed with PCOS or suspects they may have it, this name change is more than symbolic. It signals a shift in how the condition should be understood, diagnosed and treated: as a multisystem hormonal and metabolic disorder, not simply a reproductive issue.
It also highlights how interconnected hormonal health is with other areas of wellbeing, including gut function, skin health, energy and mood. Metabolic imbalances, which sit at the core of PMOS, are closely linked to gut microbiome health, inflammation and how the body processes nutrients. For women managing this condition, supporting metabolic and gut health alongside medical care may be an important part of a long-term approach to wellbeing.
Earlier diagnosis, clearer communication between specialists and a more accurate understanding of the condition's true nature may help the millions of women who have felt dismissed, confused or undertreated for years.
Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext